第一作者:
Robert F,Spiera
第一单位:
From the Hospital for Special Surgery, Weill Cornell Medical College, New York (R.F.S.), and Regeneron Pharmaceuticals, Tarrytown (A.G., M.C.N., B.A., R.B., G.D.Y.) - both in New York; the Vasculitis and Glomerulonephritis Center, Massachusetts General Hospital, Harvard Medical School, Boston (S.U.), and Sanofi, Cambridge (J.S., N.P.) - both in Massachusetts; the Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN (K.J.W.); Sanofi, Bridgewater, NJ (W.W., Y.L.); the Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin (F.B.); CHRU de Brest, Service de Rhumatologie, Brest (V.D.-P.), and Sanofi, Chilly-Mazarin (F.M.) - both in France; the Division of Rheumatology and Immunology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland (A.R.-R.); and Anglia Ruskin University, Cambridge, United Kingdom (B.D.).
作者:
主题词
人类(Humans);糖皮质激素类(Glucocorticoids);白细胞介素6(Interleukin-6);风湿性多肌痛(Polymyalgia Rheumatica);泼尼松(Prednisone);复发(Recurrence);治疗结果(Treatment Outcome);C反应蛋白质(C-Reactive Protein)
DOI
10.1056/NEJMoa2303452
PMID
37792612
发布时间
2023-10-06
- 浏览1

The New England journal of medicine
1263-1272页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文